StockData
Onconetix, Inc. logo

Onconetix, Inc. (ONCO) stock

ONCONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$3.00+0.09 (+3.09%)

Close on Nov 17, 2026Market cap $11.85MP/E –Yield –

Onconetix r&d expenses

Research and development expenses are spending on new products and technology.

Onconetix's R&D Expenses for the twelve months ending Dec 31, 2022 was $4.13M, up 211.7% year over year. For fiscal 2024 it was $154.36K, down 92.1% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2024Dec 31, 2024$154.36K-92.1%
FY2023Dec 31, 2023$1.95M-52.8%
FY2022Dec 31, 2022$4.13M+211.7%
FY2021Dec 31, 2021$1.33M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2025Mar 31, 2025$24.46K-98.0%
Q3 FY2024Sep 30, 2024$109.37K-90.7%
Q1 FY2024Mar 31, 2024$48.96K-96.2%
Q3 FY2023Sep 30, 2023$219.24K-51.8%
Q4 FY2022Dec 31, 2022$1.21M+175.7%
Q3 FY2022Sep 30, 2022$1.18M+335.5%
Q2 FY2022Jun 30, 2022$1.29M+144.3%
Q1 FY2022Mar 31, 2022$455.09K+415.8%
Q4 FY2021Dec 31, 2021$437.33K–
Q3 FY2021Sep 30, 2021$269.93K–
Q2 FY2021Jun 30, 2021$529.54K–
Q1 FY2021Mar 31, 2021$88.24K–

More Onconetix figures

See a number that looks wrong?